U.S., Sept. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07824843) titled 'Safety Study of GMDTC Injection in Participants With Solid Tumors and Cisplatin-Induced Renal Dysfunction' on Sept. 03.
Brief Summary: This trial is a multicenter, combined hydration, multiple-dose, dose-escalation phase Ib clinical study, designed to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics of the injection product GMDTC in participants with solid tumors and cisplatin-induced mild renal impairment.
Study Start Date: Oct., 2026
Study Type: INTERVENTIONAL
Condition:
Cisplatin Nephrotoxicity
Cisplatin Adverse Reaction
Intervention:
DRUG: GMDTC 1 mg/ml
Cohort 1: Participants will re...